The funding announcement for osimertinib is a breath of equity because it meets the greatest treatment need right now.

Osimertinib is the gold standard for EGFR, stage 4, Non-Small Cell Lung Cancer (NSCLC) and it will be life changing for patients and their families.

We want to acknowledge the leaders and clinical advisors at Pharmac and the key people at AstraZeneca for getting this across the line.

#accesstotreatmentisaccesstolife